Although the follitropin delta dosing algorithm was originally developed to minimize the risk of OHSS in protocols utilizing hCG as the trigger [14], there are no prior studies exploring its performance at higher doses within the new safety paradigm offered by GnRH agonists. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.